XPHYF - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy
- XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin
- This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy
- The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes
- XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023
For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the company and a significant milestone for its rapid point-of-care (“POC”) diagnostic business strategy.
XPhyto describes Covid-ID Lab as a “25-minute testing revolution” (https://ibn.fm/4erIO). It is specifically designed to offer reliable Covid-19 test results in under 25 minutes while offering various other benefits, including eliminating unnecessary...
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at http://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.